Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid

Élément Dublin CoreValeurLangue
dc.contributor.authorMahmoudi, Souha-
dc.contributor.authorSamadi, Pershia-
dc.contributor.authorGilbert, François-
dc.contributor.authorOuattara, Bazoumana-
dc.contributor.authorMorissette, Marc-
dc.contributor.authorGrégoire, Laurent-
dc.contributor.authorRouillard, Claude-
dc.contributor.authorDi Paolo, Thérèse-
dc.contributor.authorLévesque, Daniel-
dc.description.abstractWe have previously shown that docosahexaenoic acid (DHA) significantly reduced L-Dopa-induced dyskinesia (LID) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys (Samadi et al., Ann. Neurol. 59:282–288, 2006). In the present study, we measured for the first time mRNA levels of Nur77, an orphan nuclear receptor that participates to adaptive and/or aberrant dopamine-related behaviors, and retinoid X receptor γ1 (RXRγ1), a putative brain receptor for DHA and transcriptional partner of Nur77, in MPTP monkeys treated with L-Dopa and DHA. The RXRγ1 mRNA is strongly expressed in monkey caudate nucleus and putamen, but no change in levels of RXRγ1 was observed following MPTP and L-Dopa treatments. On the other hand, denervation reduced Nur77 mRNA levels, whereas chronic L-Dopa treatment strongly induced Nur77 transcripts. These modulations are taking place in substance P positive cells and are associated with both caudate-putamen matrix and striosome compartments. Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes. This is accompanied by a significant inverse correlation between Nur77 mRNA levels and dyskinetic scores. Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson's disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop
dc.publisherBlackwell Sciencefr
dc.subjectRetinoid X receptor (RXR)fr
dc.subjectMPTP-treated monkeyfr
dc.subjectParkinson’s diseasefr
dc.subjectL-Dopa-induced dyskinesia (LID)fr
dc.subjectSubstance Pfr
dc.subjectBasal gangliafr
dc.subjectCaudate nucleusfr
dc.titleNur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acidfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationNeurobiology of Disease, Vol. 36 (1), 213–222 (2009)fr
dc.subject.rvmAcide docosahexaénoïquefr
dc.subject.rvmARN messagerfr
dc.subject.rvmSinges (Animaux de laboratoire)fr
dc.subject.rvmNoyaux gris centrauxfr
dc.subject.rvmSubstance Pfr
dc.subject.rvmNoyau caudéfr
dc.subject.rvmCorps striéfr
dc.subject.rvmMaladie de Parkinsonfr
rioxxterms.versionAccepted Manuscriptfr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
rioxxterms.project.funder_nameParkinson Society Canadafr
rioxxterms.project.funder_nameParkinson’s Disease Foundationfr
bul.rights.periodeEmbargo12 moisfr
Collection :Articles publiés dans des revues avec comité de lecture

Fichier(s) :
Description TailleFormat 
nihms5154.pdf1.37 MBAdobe PDFMiniature
Tous les documents dans CorpusUL sont protégés par la Loi sur le droit d'auteur du Canada.